Bergen, 03 May 2022
Reference is made to the stock exchange announcement by Lifecare AS (the “Company”) on 20 April 2022 regarding the share issue resolved by the board of directors as part of the previously agreed consideration from Lifecare AS to acquire Lifecare Laboratories GmbH (formely named Pfützner Science and Health GmbH). The share capital increase has now been registered with the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret). The new share capital of the Company is NOK 39,896,409.20, divided into 99,741,023 shares, each with a nominal value of NOK 0.4
This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized implantable long-term sensor for correct and continuous monitoring of blood sugar in people with diabetes. The Company’s patented technology also has the potential for use in various biomarkers. Lifecare AS is listed on Euronext Growth (LIFE).
Further information: Joacim Holter, CEO, Lifecare AS, firstname.lastname@example.org, +47 40 05 90 40
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Kine Hereid, Investor Relations at Lifecare AS, on 03 May 2022 at 16:00 CET.